Kiladjian, Jean-Jacques http://orcid.org/0000-0002-8121-438X
Klade, Christoph
Georgiev, Pencho
Krochmalczyk, Dorota
Gercheva-Kyuchukova, Liana
Egyed, Miklos
Dulicek, Petr
Illes, Arpad
Pylypenko, Halyna
Sivcheva, Lylia
Mayer, Jiří
Yablokova, Vera
Krejcy, Kurt
Empson, Victoria
Hasselbalch, Hans C. http://orcid.org/0000-0003-3936-8032
Kralovics, Robert http://orcid.org/0000-0002-6997-8539
Gisslinger, Heinz
Kiladjian, Jean-Jacques
Georgiev, Pencho
Krochmalczyk, Dorota
Gercheva-Kyuchukova, Liana
Egyed, Miklos
Dulicek, Petr
Illes, Arpad
Pylypenko, Halyna
Sivcheva, Lylia
Mayer, Jiří
Yablokova, Vera
Gisslinger, Heinz
,
Funding for this research was provided by:
AOP Orphan Pharmaceuticals AG
Article History
Received: 25 December 2021
Revised: 27 January 2022
Accepted: 7 February 2022
First Online: 24 February 2022
Competing interests
: JJK reports grants and personal fees from AOP Orphan, and personal fees from Novartis, BMS/Celgene, Abbvie and PharmaEssentia. CK, KK, and VE report that they are employees of AOP Orphan. JM reports grants from AOP Orphan. RK reports personal fees from AOP Orphan Pharmaceuticals, PharmaEssentia, Qiagen and Novartis and stock ownership in MyeloPro Diagnostics and Research. HH reports Data Monitoring Board honoraria from AOP Orphan and grants from Novartis. HG reports grants and personal fees from AOP Orphan, grants and personal fees from Novartis and personal fees from PharmaEssentia, MyeloPro Diagnostics and Research, Janssen-Cilag, Roche, and Celgene. The remaining authors declare no competing financial interests.